Surprisingly, in normal prostate tissues [27,28], SLC22A3 expression showed no effects on any of the three genotypes (C/C, C/T and T/T), while in prostate cancer tissues [27], patients with a C/T heterozygous background exhibited higher transcription levels of SLC22A3 than those with C/C or T/T homozygous alleles (Figure 2A,B). This evidence concerns the gene SLC22A3 and prostate carcinoma.